title: Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
abstract: In the Asia-Pacific region, Candida albicans is the predominant Candida species causing invasive candidiasis/candidemia in Australia, Japan, Korea, Hong Kong, Malaysia, Singapore and Thailand whereas C. tropicalis is the most frequently encountered Candida species in Pakistan and India. Invasive isolates of C. albicans, C. parapsilosis complex and C. tropicalis remain highly susceptible to fluconazole (>90% susceptible). Fluconazole resistance (6.8-15%), isolates with the non-wild-type phenotype for itraconazole susceptibility (3.9-10%) and voriconazole (5-17.8%), and echinocandin resistance (2.1-2.2% in anidulafungin and 2.2% in micafungin) among invasive C. glabrata complex isolates are increasing in prevalence. Moreover, not all isolates of C. tropicalis have been shown to be susceptible to fluconazole (nonsusceptible rate, 5.7-11.6% in China) or voriconazole (nonsusceptible rate, 5.7-9.6% in China).
authors.affiliation: Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.|Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
authors.forename: He
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
authors.forename: Ying-Chun
authors.initials: YC
authors.lastname: Xu
authors.affiliation: Departments of Laboratory Medicine & Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
authors.forename: Po-Ren
authors.initials: PR
authors.lastname: Hsueh
mesh_terms: D000077612:Anidulafungin; D000935:Antifungal Agents / Q000627:therapeutic use; D001208:Asia / Q000453:epidemiology; D001393:Azoles / Q000627:therapeutic use; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity*; D002176:Candida albicans / Q000187:drug effects / Q000472:pathogenicity; D041221:Candida glabrata / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity; D041022:Candida tropicalis / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity; D058387:Candidemia / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology*; D002177:Candidiasis; D058365:Candidiasis, Invasive / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D025141:Drug Resistance, Fungal / Q000187:drug effects; D054714:Echinocandins / Q000627:therapeutic use*; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D017964:Itraconazole / Q000627:therapeutic use; D055666:Lipopeptides / Q000627:therapeutic use; D000077551:Micafungin; D008826:Microbial Sensitivity Tests; D010641:Phenotype; D015995:Prevalence; D065819:Voriconazole / Q000627:therapeutic use
chemical_list: D000935:Antifungal Agents; D001393:Azoles; D054714:Echinocandins; D055666:Lipopeptides; D017964:Itraconazole; D015725:Fluconazole; D000077612:Anidulafungin; D065819:Voriconazole; D000077551:Micafungin
keywords: Asia-Pacific region; antifungal susceptibility; candidemia; invasive candidiasis